<DOC>
	<DOC>NCT02869789</DOC>
	<brief_summary>A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Histologically confirmed Stage 4 or recurrent nonsmall cell lung cancer Eastern Cooperative Oncology Group (ECOG) score 01 (Physically able to carry out light housework or office work through to being fully active as you were before cancer) No prior systemic anticancer therapy (including EGFR and ALK inhibitors) Tissue or Programmed deathligand 1 (PDL1) results available Untreated brain metastases An active malignancy that requires concurrent intervention Active, known or suspected autoimmune disease Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>